Nav: Home

Ross River virus battle breakthrough

September 07, 2016

Research conducted by Griffith University and Melbourne-based company Paradigm Biopharmaceuticals Limited (ASX: PAR) has uncovered a potential new therapeutic treatment for the global battle against mosquito-borne alphavirus infections, including the debilitating Ross River Virus (RRV) and Chikungunya Virus (CHIKV).

Currently RRV and CHIKV sufferers are only offered symptomatic management in the form of either non-steroidal anti-inflammatories or corticosteroids, which in some cases may actually exacerbate the condition.

These therapeutics may offer some short-term symptomatic relief but their use often results in detrimental side-effects while failing to treat the underlying disease.

Researchers at Griffith University may have discovered a breakthrough in the treatment of mosquito transmitted viral diseases like RRV and CHIKV.

Pre-clinical experiments conducted by researchers at Griffith University's Institute for Glycomics on the Gold Coast have demonstrated world-first results showing that the historic drug, pentosan polysulfate sodium (PPS), can successfully treat both the acute and chronic disease manifestations symptoms of alphavirus infections in the animal model.

Several human patients have also been treated with PPS under the Therapeutic Goods Administration Special Access Scheme. These patients, who previously were severely debilitated and had difficulty with daily activities, have reported remarkable improvements in their physical capabilities and general well-being. In these RRV patients treated with PPS the results demonstrate the drug was well tolerated and produced strong signals of clinical effects.

Queensland man Jon Chaseling said, "I suffered the effects of Ross River Fever for years. Most days I found it nearly impossible to do something as simple as walking down a flight of stairs. I avoided shaking hands with people because of the pain it caused. Even the weight of the bedclothes at night was agonising. Since undergoing a course of treatment with PPS, I find I'm far more mobile and in much less pain. It's literally changed my life."

Lead researcher, Dr Lara Herrero, became interested in alphaviruses after becoming infected with Ross River virus in Western Australia in 2004.

"Alphavirus infection is characterised by crippling musculoskeletal pain, inflammation and swelling in the joints, often leading to the destruction of cartilage," she said. "Currently there's only symptomatic relief available to RRV and CHIKV sufferers with the use of either non-steroidal anti-inflammatories or corticosteroids, both which can have detrimental side-effects and in some cases may actually exacerbate the condition. But when PPS was used to treat the viral disease in the mouse model, we observed a significant reduction in musculoskeletal damage. These data point to PPS being a well-tolerated anti-inflammatory therapy and also a disease modifying drug by protecting the joint cartilage".

"We're extremely encouraged by the preclinical results and five clinical cases but our next step is to confirm these results in a Phase 2 clinical trial" said Mr Paul Rennie, CEO of Paradigm Biopharmaceuticals.

Griffith University and Paradigm Biopharmaceuticals have entered into a commercialisation agreement under which Paradigm will fund and undertake the necessary clinical trials. If the trials are successful Griffith University will receive a royalty on Paradigm's sale of the drug to treat viral arthritis.
-end-
About Ross River Virus and Chikungunya Virus

Ross River virus is a mosquito-transmitted alphavirus that causes epidemic polyarthritis and bone pain. It is Australia's most common arbovirus with about five thousand cases notified each year. [Ref: Australian Family Physician Vol 36 No. 8 Aug 2009]

Chikungunya virus, also a mosquito transmitted alphavirus, originated in Africa and has since expanded its global range with outbreaks occurring in several other continents. In 2006-2007 a large outbreak of chikungunya occurred in India with several other countries in South-East Asia also affected. Since 2005, India, Indonesia, Maldives, Myanmar and Thailand have reported over 1.9 million cases. In 2007 transmission was reported for the first time in Europe with the first case originating from a returned traveller. In late 2013, chikungunya virus was found for the first time in the Americas on islands in the Caribbean also in South America - areas in which chikungunya was not previously transmitted. Local transmission has also occurred in the United States, where the virus was previously unknown. Experts predict is just a matter of time before local transmission occurs in Australia. There is a risk that the virus will be imported to new areas by infected travellers. As noted previously, there is no vaccine to prevent or drugs to treat Ross River or chikungunya virus infections. [Ref: WHO website, CDC website and Time.com]

About the Institute for Glycomics

The Institute for Glycomics is a flagship biomedical research institute at Griffith University's Gold Coast Campus. Since its inception in 2000, the Institute for Glycomics quickly became recognised as one of the largest in the world with a core focus on this complex and emerging field of research. It was the glycomics approach that led to the discovery of the world's first drug against the influenza virus, Relenza®, and the award of the Australia Prize to the Director of the Institute for Glycomics, Professor Mark von Itzstein.

Today, the Institute has some of Australia's most renowned research leaders and state-of-the-art facilities. The unique, multidisciplinary approach and extraordinary research capacity is now being used to develop the next generation of drugs and vaccines to fight diseases of global impact.

About Paradigm Biopharmaceuticals Ltd:

Paradigm Biopharmaceuticals Ltd (ASX: PAR) is an Australian biopharmaceutical company focused on repurposing the historic drug PPS (Pentosan Polysulfate Sodium) as a potential new treatment for Bone Marrow Edema (BME) lesions following traumatic injury. Paradigm Biopharmaceuticals is also repurposing PPS for respiratory diseases including Allergic Rhinitis (AR) also known as hay fever. Repurposing an existing drug diminishes early developmental risks associated with traditional new drug development and usually means shorter development times, lower development costs and less safety risk.

ABN: 94 169 346 963
http://paradigmbiopharma.com

Griffith University

Related Pain Articles:

Spinal manipulation treatment for low back pain associated with modest improvement in pain, function
Among patients with acute low back pain, spinal manipulation therapy was associated with modest improvements in pain and function at up to six weeks, with temporary minor musculoskeletal harms, according to a study published by JAMA.
Pain in the neck
Researchers led by University of Utah bioengineering assistant professor Robby Bowles have discovered a way to curb chronic pain by modulating genes that reduce tissue- and cell-damaging inflammation.
Can staying active help to prevent chronic pain? Physical activity affects pain modulation in older adults
Older adults with higher levels of physical activity have pain modulation patterns that might help lower their risk of developing chronic pain, reports a study in PAINĀ®, the official publication of the International Association for the Study of Pain (IASP).
Is back pain killing us?
Older people who suffer from back pain have a 13 per cent increased risk of dying from any cause, University of Sydney research has found.
Improving pain care through implementation of the Stepped Care Model for Pain Management
A new study published in the Journal of Pain Research provides evidence that implementation of a Stepped Care Model for Pain Management has the potential to more adequately treat chronic pain.
Surgery for back pain reduces problems with sex life-related pain
For patients with degenerative spinal disease, surgery is more effective in reducing pain that interferes with sexual activity, compared to nonsurgical treatment, reports a study in the Nov.
'Pain paradox' discovery provides route to new pain control drugs
A natural substance known to activate pain in the central nervous system has been found to have the opposite effect in other parts of the body, potentially paving the way to new methods of pain control.
Treating pain without feeding addiction: Study shows promise of non-drug pain management
A new study shows the potential for patients who have both addiction issues and chronic pain to get relief from an approach that combines behavioral therapy and social support to help them manage their pain without painkillers that carry an addiction risk.
Neuropathic pain unmasks subliminal excitation in pain processing circuits
Research by Steven Prescott, at Toronto's Hospital for Sick Children, sheds new light on the mechanism underlying the establishment of neuropathic pain.
The anatomy of pain
Emotions consist of general components that are also elicited by similar impressions and specific components.

Related Pain Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...